Miami, Florida – Global Stem Cells Group (GSCG) and its educational division, the International Society for Stem Cell Application (ISSCA), have successfully concluded two major events in their 2025 international educational series: the International Regenerative Medicine Conference in Bogotá, Colombia, and the International Regenerative Medicine Conference and Certifications in Cancún, Mexico.
Both gatherings brought together physicians, researchers, and healthcare professionals from across the world to exchange knowledge and explore the latest advancements in regenerative medicine, cellular therapies, and peptide science. With these two conferences, ISSCA has now held more than twelve international conferences so far this year, reaffirming its ongoing commitment to physician education, scientific collaboration, and the responsible advancement of regenerative technologies.
Conference and Scientific Highlights from Colombia
The Bogotá Conference was held on October 24–25, 2025, at the W Hotel, featuring a comprehensive scientific agenda developed by the ISSCA Scientific Committee. International experts presented cutting-edge topics such as exosomes, peptides, NAD+, and MUSE cells.
Distinguished speakers included Lauren Fitzgerald, MD (USA), on peptide-based clinical optimization; Brandon Sassouni, MSc (USA), on MUSE cells and exosome therapeutics; Andrea Lapeire, MD (Argentina), ISSCA LATAM Director; Richard Silva, DO (USA), on functional regenerative applications; and Rafael Moguel, MD (Mexico), on cardiovascular regeneration.
The conference concluded with MedConnect, ISSCA’s signature international networking cocktail event, featuring an upscale social experience with canapés, beverages, live music, and performance showcases, while fostering high-level collaboration between physicians, researchers, and regenerative medicine organizations worldwide.
Conference and Certifications in Cancún
From November 7–9, 2025, ISSCA and GSCG hosted the International Regenerative Medicine Conference in Cancún at the InterContinental Presidente Cancún Resort, followed by three specialized certification programs:
- Stem Cell Therapies Certification – covering clinical applications of mesenchymal and MUSE cells, exosome integration, and regenerative treatment protocols.
- Advanced Peptide Certification – focused on molecular mechanisms, clinical design, and patient-oriented peptide protocols for longevity, performance, and metabolic balance.
- MSK / Sports Medicine Certification – emphasizing regenerative techniques for orthopedic and sports-related injuries, including PRP, exosome, and peptide-based recovery strategies.
Keynote presentations were delivered by Greg Jones, NMD, ABAAHP (USA) on peptide-based preventive medicine; Jason Pencek, DC, FNP (USA) on mitochondrial repair and integrative peptide strategies; Prof. Dr. Roni Moya (Portugal) on immune engineering and translational applications; Márcio Kume, MD, PhD (Brazil) on musculoskeletal regeneration and orthopedic innovation; Wajid Burad, MD (Mexico) on sports performance and non-surgical interventions; and Brandon Sassouni, MSc (USA) on advancements in universal cell applications.
“These programs are designed to provide physicians with practical, evidence-based tools that they can apply directly in their medical practice,” said Benito Novas, Founder of ISSCA. “We believe that combining scientific discussion with structured certifications ensures a more complete and responsible approach to regenerative medicine education.”
Dave Christensen, CEO of Regenerative Medical Technology Group Corp. (parent to GSCG), added:
“The participation and engagement seen in both Colombia and Cancún demonstrate the strong interest among physicians in expanding their knowledge in regenerative and peptide-based medicine. These events continue to strengthen the foundation for ongoing collaboration between science and clinical practice.”
Upcoming Educational Events
Before the end of the year, ISSCA and GSCG will continue their educational calendar with two additional international conferences:
- Lima, Peru – November 28–30, 2025
- San Juan, Puerto Rico – December 5–6, 2025
Both upcoming conferences will maintain the organization’s multidisciplinary format, combining theoretical lectures, certification modules, and hands-on workshops covering stem cell therapy, peptide applications, and musculoskeletal repair.
Looking ahead, Global Stem Cells Group and ISSCA are preparing a robust educational program for 2026, which already includes events in more than 15 countries across Latin America, Europe, the Middle East, and Asia. The goal is to continue facilitating responsible scientific education, networking, and professional development for physicians dedicated to regenerative and cellular medicine.
About the International Society for Stem Cell Application (ISSCA)
ISSCA, a division of Global Stem Cells Group, focuses on education, certification, and professional development in regenerative medicine and cellular therapies. With over 15 years of global experience, ISSCA designs and delivers multidisciplinary programs that connect scientific innovation with real-world clinical application.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is an international organization dedicated to advancing regenerative medicine through research, product development, and physician education. The company provides access to the latest biologic innovations, clinical tools, and specialized training to support the safe and effective practice of regenerative therapies.
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
